Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors

Area of Science:

• Oncology
• Immunology
• Epigenetics

Background:

• Immune surveillance balances coinhibitory and costimulatory signals to control tumor development.
• Immunotherapy shows durable benefit in immunogenic tumors, but modest responses in others.
• Checkpoint inhibitors may require combination strategies to boost anti-tumor immunity.

Purpose of the Study:

• To review the current understanding of combining epigenetic drugs with immunotherapy.
• To focus on how epigenetic drugs prime the immune response for checkpoint blockade therapy.

Main Methods:

• Literature review of epigenetic drugs and immunotherapy combinations.
• Analysis of epigenetic drug mechanisms in modulating the tumor immune microenvironment.
• Focus on immune response priming in the context of checkpoint blockade.

Main Results:

• Epigenetic aberrations are significant contributors to carcinogenesis.
• Epigenetic drugs can prime anti-tumor immune responses.
• These drugs increase tumor-associated antigen expression and immune-related genes.
• Modulation of chemokines and cytokines enhances immune cell activation.

Conclusions:

• Combining epigenetic drugs with immunotherapy is a promising strategy.
• Epigenetic therapy can enhance the efficacy of checkpoint blockade.
• This combination approach may improve treatment outcomes for non-immunogenic tumors.